As the deadline set by the National Development and Reform Commission on July 1 approaching, Shanghai, Hubei, Jiangxi, Jilin and other provinces and cities have announced the list of low-cost drugs. It took two days for reporters to clarify these lists because the provinces in Henan and Yunnan added too many varieties of the province, but they also had to make different dosage forms for varieties on the national catalog. If such circumstances evolve, it will inevitably lead to melee in pharmaceutical companies. The original intention of the policy may have to become bad.

Among the provinces and cities that have published catalogs, Jiangxi has only announced the list of low-priced medicines within the pricing scope of the provincial development and reform commission, adding 2 western medicines and 6 traditional Chinese medicines, while Fujian supplemented 7 western medicines and 10 traditional Chinese medicines. Shanghai and Hubei added more varieties, Hubei added 13 western medicine, 32 traditional Chinese medicines and 5 ethnic medicines, Shanghai added 75 western medicines, 67 varieties of traditional Chinese medicine, the two provinces directory will be the national varieties and provinces Supplementary varieties listed in the city, at a glance. Jilin, Henan and Yunnan are hybrids of various breeds. Yunnan and Henan Provinces have replaced many national breeds with provincial breeds, and many different national breeds have changed their dosage forms.

At the end of May, the National Development and Reform Commission held a special meeting to require provincial and municipal competent departments to calculate the price of low-price medicine and drug, and could not be declared by the enterprise, and submitted an application and the Price Bureau for examination. Besides, Varieties combing, not to consider other forms of species, in particular, companies take the initiative to lower prices into the list. I do not know why some places come up with so many provincial varieties?

In early May, the state low-cost drug policy and directory release, pharmaceutical companies a good voice, and now it may not necessarily be positive. According to the catalogs published by various provinces and cities at present, there are three major differences in the varieties: first, there are exclusive varieties in different provinces or cities or varieties with fewer than five manufacturers, and the exclusive varieties in one province are often not the other The province's exclusive varieties; the second is that some national catalogs of the exclusive varieties did not appear in the provincial directory; Third, the provincial catalogs common in the local exclusive varieties, it is inevitable to take care of the local pharmaceutical companies suspicion. Such an operation will make the pharmaceutical companies work hard to deal with, and increase the risk of corruption and rent-seeking.

In the premise of the total market capacity remains unchanged, the launch of the list of low-cost drugs to the pharmaceutical market is a balanced break, means to re-shuffle. Therefore, the pharmaceutical companies have tried their best to squeeze into the catalog of natural motivation, the parties concerned, such as control can easily lead to corruption.

In 2009, the state implemented the basic drug policy, but because it was not implemented well, it caused the hospital to wait and see or could not effectively implement it and affected the subsequent policy launch. Judging from the current trend, the chaotic situation of low-priced drugs may lead to more wait-and-see hospitals, and the original intention of the policy can hardly be fully realized.

For the pharmaceutical companies, the low-cost drugs of their own led to changes in market structure, increased sales of pharmaceutical companies management, market maintenance, the difficulty and cost. Some hospitals that have already entered the catalog may not be able to achieve good results because of disguised opposition from hospitals. Therefore, with the exception of some large enterprises, the cost of some small and medium-sized drug companies will increase, and the benefits will not be worth the effort.

After the policy of low-cost medicine comes out, some places have evolved from the initial conflict to the ones that can not be resolved afterwards. Relevant departments should face up to this issue, pay attention to the risks that may arise and timely rectify their mistakes.